View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 6, 2017

Achillion commences dosing in Phase II trial of ACH-4471 to treat PNH

US-based biotechnology company Achillion Pharmaceuticals has commenced dosing patients in a Phase II clinical trial of ACH-4471 for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

US-based biotechnology company Achillion Pharmaceuticals has commenced dosing patients in a Phase II clinical trial of ACH-4471 for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

ACH-4471 is an orally administered, small-molecule inhibitor of factor D with potential to address intravascular and extravascular hemolysis by blocking the amplification loop of the complement alternative pathway.

The proof-of-concept Phase II trial is designed to evaluate the safety, efficacy and pharmacokinetics of ACH-4471 in untreated patients.

Achillion president and chief executive officer Milind Deshpande said: “We are pleased to have begun this trial in PNH patients to evaluate ACH-4471, the first orally administered factor D inhibitor to have demonstrated complement alternative pathway (AP) inhibition in humans, which represents a potentially novel and unique mechanistic approach to treating this life-threatening disease."

"The proof-of-concept Phase II trial is designed to evaluate the safety, efficacy and pharmacokinetics of ACH-4471 in untreated patients."

The trial design includes intra-patient dose-escalation from an initial 100mg administered thrice daily.

The primary objective of the trial is measure of the change in the levels of intravascular hemolysis' sensitive biomarker known as serum lactate dehydrogenase (LDH), through 28 days of dosing.

The trial will also examine secondary endpoints such as changes in levels of haemoglobin and red blood cells, and complement pathway biomarkers such as Bb and factor D.

It is expected that the trial's interim results will be available in the second quarter of this year.

Achillion plans to further investigate ACH-4471 in a Phase II trial to treat C3 glomerulopathy patients, alongside the study of extended release formulations to minimise the dosing frequency.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena